Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
EVENTS PER QUARTER · HOVER FOR EMPLOYEE COUNTS
Medtronic, Inc. has announced layoffs affecting 81 employees in its Diabetes division as part of preparations for the separation of its MiniMed business. This decision comes as the company restructures its operations ahead of the planned spin-off. The layoffs are a strategic move to streamline the workforce and focus on core business areas. While the specific locations of the affected employees were not disclosed, the restructuring reflects Medtronic's ongoing efforts to enhance operational efficiency during this transitional phase.
Medtronic plc has announced the layoff of 81 employees at its diabetes site in California. This decision reflects the company's ongoing efforts to streamline operations and adapt to changing market conditions. The layoffs are part of a broader strategy to enhance efficiency within the organization. Medtronic's diabetes division has faced challenges, prompting this workforce reduction to better align resources with current business needs. The affected employees will be notified as part of the company's restructuring efforts.
Medtronic plc has announced plans to lay off approximately 2,000 employees as part of a restructuring effort set to begin in January 2026. The layoffs are part of a broader strategy to streamline operations and reduce costs amid ongoing challenges in the medical technology sector. The company, headquartered in Dublin, Ireland, is facing increased competition and regulatory pressures, prompting this significant workforce reduction. The layoffs are expected to impact various departments as Medtronic seeks to enhance its operational efficiency and focus on core business areas.
Medtronic plc has laid off 81 employees as part of its transition related to the spin-off of its diabetes business. This decision comes as the company restructures its operations to focus on its core areas. The layoffs are part of a broader strategy to streamline the workforce during this significant business transition. The affected employees were notified recently, and the company is working to support them during this change.
Medtronic plc has recently laid off approximately 300 employees in its Packaging department, effective October 1, 2023. This decision comes as part of a broader strategy to enhance operational efficiency and sustainability within the company. The layoffs are expected to have significant implications for the company's packaging sustainability initiatives, as the reduced workforce may impact ongoing projects and innovations. Medtronic's management has indicated that these changes are necessary to align with evolving market demands and to streamline operations. The layoffs reflect the company's commitment to maintaining competitiveness in a challenging economic environment.
Medtronic plc has announced plans to close its California site as part of a restructuring effort. This decision is part of a broader strategy to streamline operations and improve efficiency within the company. While specific details regarding the number of employees affected have not been disclosed, the closure indicates a significant shift in Medtronic's operational focus. The company aims to enhance its overall performance and adapt to changing market conditions. Further details about the timeline for the closure and potential layoffs are expected to be clarified in the coming months.
No one has shared a story from Medtronic plc. yet. Went through a layoff here? Your experience helps others feel less alone.
Share your story →We'll email you the moment a new layoff is reported here.